A Review on Novel Approaches for Cure, Diagnosis, Treatment and Future Direction in Polycythemia

Ankita Damahe; Khilendra Kumar Sahu; Antra Sahu; Chunesh kumar; Devki Markande; Nilesh kumar; Janvi NilMarkar

doi:10.5281/zenodo.14852627

Review Paper | Open Access
Volume 02 | Issue 02 | Article Id IJSRT/250302022

A Review on Novel Approaches for Cure, Diagnosis, Treatment and Future Direction in Polycythemia
Ankita Damahe* Khilendra Kumar Sahu Antra Sahu Chunesh kumar Devki Markande Nilesh kumar Janvi NilMarkar
Apollo College of Pharmacy Anjora ,Durg 491001 ,(C.G) , India?

Abstract

An excess of red blood cells in the body is known as polycythemia. The blood becomes thicker due to the additional cells, which raises the risk of blood clots and other health problems. There are various causes of polycythemia, and each one has a unique course of treatment. Discover more about polycythemia's causes, symptoms, and available treatments in this article. An rise in hemoglobin or hematocrit levels over the standard values is known as polycythemia. The majority of its causes are linked to the development of hyper viscosity, and the majority of cases are classified as primary or secondary polycythemia (SP). The underlying disease of the former, often referred to as polycythemia vera (PV), affects the bone marrow itself, whereas the latter is typified by an overabundance of stimulation of cell creation in the normal bone marrow. This study included patients who were diagnosed with PV or SP after undergoing additional testing at our hospital from January 2020 to December 2023 after polycythemia was discovered. The 2016 WHO criteria (hemoglobin > 16.5 mg/L for men and >16.0 mg/L for women, and/or hematocrit > 49% for men and >48% for women) were followed in determining the laboratory thresholds used to diagnose polycythemia. A case of PV exacerbated by cardiac hypertrophy is presented in this paper. It provides a full summary of the patient's long-term follow-up and a detailed account of their experience using antihypertensive medication. With an emphasis on clinical case studies, a thorough literature analysis was also carried out to look into any potential connections between PV and the risk of cardiovascular disease. The goal is to offer fresh viewpoints and understandings for evaluating cardiovascular risk and predicting prognosis in MPN patients. These findings have important ramifications for future clinical care guidelines in addition to improving our understanding of the relationship between PV and cardiovascular disease

Keywords

Polycythamia; Hypertension,Thrombosis; Cardiomyopathy Hypertrophic,Choroidal Thickness; Hematocrit; Restricted Blood Flow

Introduction

Polycythemia?or erythrocytosis, refers to an increase in the absolute?amount of?red blood?cells (RBCs)?in the body. In practice, this is reflected?as?an increase in hemoglobin levels, or hematocrit,?above?what is considered?physiological?for?a?particular age and?sex. Normal red blood cell volume usually?does not exceed 36 ml/kg in?men?and 32 ml/kg in?women. Reference?ranges for normal hemoglobin and hematocrit?levels?vary?by?altitude, ethnicity, and country^.[1]However,?for?reference, the hemoglobin and hematocrit of a healthy adult male are 16 g/dL +/- 2?g/dL?and 47% +/- 6%, respectively. The hemoglobin and hematocrit of?an adult?menstruating?woman?are?typically?13 g/dL +/- 2?g/dL?and 40% +/- 6%, respectively. Polycythemia in?neonates?is defined as a central venous hematocrit?greater than?65% or a hemoglobin value?greater than?22 g/dL^.[2] Polycythemia?vera is a?subtype?of polycythemia. Often?colloquially?referred to?simply?as ?polycythemia,? it is an?acquired?myeloproliferative?disorder with a Philadelphia chromosome negative pattern^{. [3]}?This condition?may?be associated with overproduction of all three cell?lineages,?but with a?marked?predilection?for?red blood cells. The?clinical significance of?polycythemia, regardless of?cause,?is?the associated risk of thrombotic events due to?increased blood viscosity. Furthermore, polycythemia vera may lead?to leukemia?progression, which also necessitates the implementation?of additional?therapeutic strategies^[4]. Laboratory evaluations such as serum erythropoietin levels and genetic analysis may assist in determining the cause of polycythemia when the physical examination and medical history do not indicate a probable reason. Mild polycythemia typically does not present any symptoms. The management of polycythemia is variable and generally focuses on addressing its underlying cause. Treatment for primary polycythemia (refer to polycythemia vera) may include procedures like phlebotomy, antiplatelet medications to decrease the risk of blood clots, and other cytoreductive therapies to lower the production of red blood cells in the bone marrow. Laboratory?research,?such as?the level of erythroopoettin in?serum and genetic?testing, can help?clarify the cause of?polycology?if the?patient's?physical?examination?and history do not?clarify the cause^.[5] Soft vegetation itself?is often asymptomatic.The treatment of polyconomics?varies, and?usually includes the main causes of the main cause^.[6]Treatment of primary?hyperhidrosis?(see?VERA polycacoritis) In order?to reduce?the?risk of blood?tricks?to reduce the?amount?of red blood cells?generated?in the bone?marrow, to reduce the risk of blood tricks and anticroat therapy may be included ^[7].

CLASSIFICATION

Spurious polycythemia

This?occurs due to?a decrease in the?volume?of red blood cells,?rather than an?actual?increase in?their mass. The reasons include:Severe?dehydration due to isolated fluid loss:?May be accompanied by severe?diarrhea and?vomiting. Heisbock?syndrome:?Common in obese and?hypertensive?men.?Smoking,?alcohol [abuse?and?the?use of diuretics?contribute to this.[4]

True Polycythemia

Additional stratification by?serum erythropoietin (EPO) levels as?follows:

1.Low?serum EPO levels?(primary polycythemia) Polycythemia veraPrimary?familial and congenital?polycythemia ^[52]

2.High?serum EPO level?(secondary polycythemia) High altitude Respiratory?disorders:?chronic?obstructive pulmonary disease (COPD),?Pickwick?syndrome, uncontrolled?asthma, Cyanotic?heart?disease?with right-to-left?shunts Renal?disorders:?renal?cysts,?renal?cancer, renal artery stenosis, Bartter syndrome, focal sclerosing?glomerulonephritis, Elevated?carboxyhemoglobin:?commonly?seen in smokers, people working on cars in?enclosed?spaces, or people working in boiler?rooms^[51] Hemoglobinopathies: high?hemoglobins?affinity?such as Hb Yakima,?methemoglobinemia EPO-secreting?tumors: sources include hepatomas, uterine leiomyomas, and cerebellar?hemangiomas Iatrogenic?causes:?including administration of?erythropoietin?analogues,?anabolic steroids, and testosterone replacement?therapy Neonatal polycythemia^{. [48][35]}

Etiology

The etiology of the disease process appears to be neoplastic proliferation.There is a signaling defect leading to an abnormal response to growth factors, and the abnormal clonal line interferes with normal lineage proliferation.The?JAK2 (Janus kinase 2) gene,?involved?in?intracellular?signaling,?is mutated in 90% of polycythemia vera?(PV) cases.?Cytogenetic studies?have shown that?hematopoietic progenitor cells in approximately 34% of?PV?patients?have abnormal karyotypes.?At the time of diagnosis, 20% of patients have cytogenetic abnormalities,?and this figure rises?to more than 80%?in patients?with more than 10 years of?available follow-up^[8]

Epidemiology

Polycythemia?vera (PV) can affect all?ethnicities without sexual predisposition, but occurs?slightly more?often?in men than women^.[9] It can occur?at any age,?but the?average?age?at?diagnosis is?60 years^[10]PV affects?0.6-1.6 people?per million in the United States.The incidence is lower?in Japan than in the United States?and?Europe^.[11]

Pathophysiology

The bone marrow of patients with polycythemia vera (PV) contains normal stem cells and contains abnormal clonal stem cells that suppress normal stem cell growth and maturation.The cause of panmyelosis is unregulated neoplastic proliferation.JAK2 kinase mutation likely leads to the signaling derangements resulting in PV.A valine to phenylalanine substitution at position 617 of the JAK2 gene, or JAK2V617F, leads to constitutively active cytokine receptors^.[12] ^[37]This mutation is observed in over 90% of patients with PV and 50% to 60% of primary myelofibrosis, and 50% of essential thrombocythemia^{.[13][14][35]} This process leads to increased production of red blood cells and platelets with associated complications of thrombosis and bleeding.

Treatment and?Management

There?is no cure for polycythemia vera?(PV).The goal of?treatment?is to relieve symptoms?and?reduce?the risk of complications,?such as?thrombosis, bleeding, and hematologic?changes.Currently, there is?no?treatment to prevent progression to?myelofibrosis or acute leukemia/myelodysplastic syndrome, but there are known?medications?that?may?increase this?risk and should be avoided^.[15]

Novel polycythemia vera therapies under investigation and clinical trial

Table 1

Level of Study Author	Target	Mechanism of action
Phase 2 Ongoing	Iron Metabolism Pathway Apoptosis	Hepcidin mimetic ? MDM2 inhibitor
Phase 1 Ongoing	Erythroid Lineage Differentiation	Phosphoinositide 3-kinase (PI3 K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway
Phase 2	Genetic transcription Genetic transcription	Histone deacetylase inhibitor, 3in combination with hydroxyurea Monotherapy Histone deacetylase inhibitor
Phase 1	Genetic transcription Apoptosis	Monotherapy Histone deacetylase inhibitor, MDM2 inhibitor
Animal Study	Iron Metabolism Pathway	Minihepcidin-small molecule
In-vitro	Genetic transcription Genetic transcription Erythroid Lineage Differentiation Erythroid lineage proliferation through cytokines	Histone deacetylase inhibitor,, in combination with hydroxyurea Monotherapy Histone deacetylase inhibitor, Phosphoinositide 3-kinase (PI3 K)/protein kinase B, (Akt)/mammalian target of rapamycin (mTOR) pathway Insulin receptor substrate 1/2 small molecule inhibitor

? ??

?
? ? ? ? ? ? fig 1.jpg
? ? ? ?

Medical treatment

Patients?under 60?with no?history of thrombotic events are considered low?risk?and?recommended?treatment?is as follows:

Phlebotomy: Aim for a?hematocrit?of?less than 45%.Each unit?(500 ml)?of?blood?phlebotomized?is expected to reduce?the hematocrit?of?an average-sized?adult by 3%.?Men?can?tolerate?a maximum withdrawal?of?1.5-2?units?per week, while?women, the elderly, those?weighing?less than 50 kg, or those with cardiovascular disease?can?only tolerate?a withdrawal?of 0.5 units?per?week.The?purpose?of?pulse pipe incision?is to?intentionally?induce?iron deficiency.This is to limit the abilities of the bone marrow of red blood cells?to some?extent.Therefore,?patients?do?not take iron supplements^[29]Compared to objective hematrits, vascular patients?with less than?45 %?have?a significant less than 45 % of?cardiovascular and?thrombosis events^.[16] If there?is?no contraindications, a low -dose?aspirin (40 mg?for?100?mg),?if?there is?no contraindications,?it is necessary?to?reduce thrombosis risk.[19]?Patients with platelets?exceeding?1?million /microliters?should not be placed?in?aspirin?because they may be more risky for bleeding due to phytowil brand's acquired diseases^.[17][36]Treats aspirin's intractable?symptoms.

Optimize?cardiovascular?health, including?weight loss, exercise,?smoking?cessation,?and?blood pressure control.Patients over?60 years of age and/or?those with?a history of thrombosis are considered?at higher?risk.For?high-risk patients, cytoreductive therapy is recommended in addition to phlebotomy and aspirin.The first-line?treatment?is hydroxyurea (HU) due to its safety profile, cost, and?effectiveness^.[18] ^[49]The initial dosage?is 15?mg per kg?of actual body weight per?day, given in two?divided?doses per day.?The goal is to reduce platelets to 100,000 to?400,000 / MicrolyTra?without excessive neutropenia and anemia.The dosage?should not be?regulated?more?often by?once?a week,?because?to achieve the therapeutic effect,?it takes three to five?days.For patients who do not respond?to?or cannot tolerate?hydroxyurea?therapy,?pegylated interferon or?busulfan may be tried.?Other alternatives include ruxolitinib, anagrelide, pipobroman, and radioactive?phosphorus^.[18][19]

Blood withdrawals

The most common treatment for polycythemia vera is having frequent blood withdrawals, using a needle in a vein (phlebotomy).It\'s the same procedure used for donating blood.This decreases your blood volume and reduces the number of excess blood cells.The frequency of?blood?tests?depends on the severity of?the condition^.[30]

Treatment of?itching

If you?are bothered by?itching, your doctor may?prescribe medications?such as?antihistamines to reduce the discomfort?or recommend ultraviolet light?therapy.Drugs?called selective serotonin reuptake inhibitors (SSRIs),?commonly used to treat depression, have?helped?reduce?itching in clinical trials. Examples of selective serotonin reuptake inhibitors (SSRIs) include paroxetine?(Brisdell,?Paxil, Pexeva,?and?others) or fluoxetine (Prozac, Sarafem, Selfemra,?and others)^[31].

Drugs that reduce the number of red blood cells

If phlebotomy alone?is not?enough, your doctor may?recommend?medications that can reduce the number of red blood cells in your bloodstream. Here are some examples:

??Hydroxylura?(Droxia, Hydrea)

? Interferon?alpha-2b?(Intron A)

? Ruxolitinib (Jakafi)

? Busulfan (Busulfex, Myleran)^[32]

Heart medications

Your doctor will also likely prescribe medications to control risk factors for heart and blood vessel disease, including high blood pressure, diabetes and abnormal cholesterol.Your doctor may recommend that you take a low dose of aspirin to reduce your risk of blood clots. Low-dose aspirin may also help reduce burning pain in your feet or hands^[33]

Self-care

If you've?been diagnosed with polycythemia?vera, there are steps you can take to feel better.Try:

??Exercise.?Moderate exercise, such as walking,?gets the?blood?flowing.?This helps?reduce the?risk of blood clots.Stretching?and?exercising your legs?and?ankles can?also improve circulation.

??Avoid?tobacco.Smoking?can cause your blood vessels to narrow, increasing?your?risk of heart attack or stroke due to blood?clots.

??Avoid low-oxygen?environments.Life in highlands,?skiing or?mountain?climbing in?the?mountains?still?reduce the?level of?oxygen in?the blood.

? Be?kind?to your?skin -Swim with cold water to?reduce?itching and stroke the skin using?a?soft cleansing agent.?Adding?a starch?such as?cornstarch?to?the bathtub may?help.

Avoid hot?baths, hot?whirlpools, and hot showers or baths.

Don't hurt your skin,?as it can damage?the?skin and increase the risk of infection.

Use lotion to?wet?your?skin.

??Avoid extreme?temperatures.?Poor?circulation?increases?the?risk of injury from hot and cold temperatures.

Always wear warm clothing during?cold weather,?especially?your?arms?and?legs.?In hot weather, protect yourself from the sun and drink plenty of?fluids.

??Watch for?ulcers.?Poor circulation can make it difficult for?ulcers?to heal,?especially?on?the?hands and feet.Check?your feet regularly and tell your doctor about?pain^.[34][35]

Heart medications

Your doctor will also prescribe medications to control risk factors for heart and?vascular?disease,?such as?high blood pressure,?diabetes,?and abnormal?cholesterol. Your?doctor may recommend?taking low-dose?aspirin to reduce?the?risk of blood clots.Low-dose aspirin may also help reduce burning pain in?the?feet?and hands.[33]

Surgical Treatment

Splenectomy?may be appropriate in cases of painful splenomegaly?and?recurrent splenic infarction.BUDD-CHIARI syndrome?or?venous liver?drainage is a surgical intervention such as?the intravenous intravenous intraorphitho?(TIPS),?Porto-Chabal Shunt, Shunt Cabal Star, Caval / Caval Midarterial Shint,?or?Sage Shunt Sage Sage.A potential complication that requires the potential complications required] [21]
Differential diagnoses to consider include

Rare mutations in?the erythropoietin (EPO) receptor can mimic the?cardinal symptoms?of PV,?such as?increased red?blood?cell mass and decreased?EPO, but?the mechanism is?not EPO-independent but rather a hypersensitive EPO?receptor?mechanism. [23][24]?Isolated granulocytosis can occur?as a result of an infection?or?leukemic reaction.Only plateletosis may be the?result?of?bleeding or iron deficiency.

Essential?thrombocythemia

Chronic myeloid?leukemia

Myeloid metaplasia of unknown origin

Chronic?myeloid leukemia

Primary?myelofibrosis

Secondary?polycythemia^[22][23][24]

Future direction

Polycythemia vera (PV) is a condition?in which?the bone marrow?is overworked?and?produces?too many red blood cells, white blood?cells,?and?platelets, which?can put you at risk for life-threatening blood clots, bleeding, and?some types of?blood?cancer.Therefore, frequent visits?to a hematologist?and?close monitoring and treatment?are important?to?reduce?these risks.Treatment options include phlebotomy, daily aspirin, and certain bone?marrow suppressant drugs^{[25,26,27,28]}

CONCLUSION

These?reviews?explore the?potential?and future?directions of various treatments to treat?or?prevent polycythemia or erythrocytosis?and its?symptoms. It provides a full summary of the patient's long-term follow-up and a detailed account of their experience using antihypertensive medication. With an emphasis on clinical case studies, a thorough literature analysis was also carried out to look into any potential connections between PV and the risk of cardiovascular disease. The goal is to offer fresh viewpoints and understandings for evaluating cardiovascular risk and predicting prognosis in MPN patients. These findings have important ramifications for future clinical care guidelines in addition to improving our understanding of the relationship between PV and cardiovascular disease.In summary,?NLR, PLR, and SII showed?remarkable?ability to?distinguish?PV from?MS.?The diagnostic?efficacy?of these three parameters in recognizing PV?was?improved when used in?combination?with EPO.EPO and SII,?and?SII alone,?have been shown?to be the most useful biomarkers for?the diagnosis of?PV.These results?indicate?that these biomarkers, especially SII,?may?serve as additional criteria in the diagnosis of PV.We?believe?that further?studies are warranted?to explore the diagnostic?improvements?achieved by?combining?SII (and other inflammatory markers)?with?EPO levels in?patients with erythrocytosis,?which?may?be?important in?facilitating the early diagnosis of PV

REFERENCE

Mandala WL, Gondwe EN, MacLennan JM, Molyneux ME, MacLennan CA. Age- and sex-related changes in hematological parameters in healthy Malawians. J Blood Med. 2017;8:123-130.
Wiswell TE, Cornish JD, Northam RS. Neonatal polycythemia: frequency of clinical manifestations and other associated findings. Pediatrics. 1986 Jul;78(1):26-30.
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008 Jan;22(1):14-22.
Pearson TC. Apparent polycythaemia. Blood Rev. 1991 Dec;5(4):205-13.
McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. (July 2005). "Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis". British Journal of Haematology. 130 (2): 174?195. doi:10.1111/j.1365-2141.2005.05535.x. PMID 16029446. S2CID 11681060
Gangat N, Szuber N, Pardanani A, Tefferi A (August 2021). "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views". Leukemia. 35 (8): 2166?2181. doi:10.1038/s41375-021-01290-6. PMC 8324477. PMID 34021251.
Spivak JL (July 2019). "How I treat polycythemia vera". Blood. 134 (4): 341?352. doi:10.1182/blood.2018834044. PMID 31151982.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kr?ger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A., European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20;29(6):761-70.
An?a BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994 Oct;47(2):89-93.
Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975 Oct;12(4):339-51.
Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006 Apr;32(3):171-3.
James C, Ugo V, Le Cou?dic JP, Staerk J, Delhommeau F, Lacout C, Gar?on L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005 Apr 28;434(7037):1144-8.
Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008 Jul 15;112(2):231-9.
Wasserman LR. The management of polycythaemia vera. Br J Haematol. 1971 Oct;21(4):371-6.
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):3.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T., CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 03;368(1):22-33.
van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997 Apr;97(1):179-84.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Feb;90(2):162-73.
B?y?ka??k Y, Ali R, Turgut M, Saydam G, Yavuz AS, ?nal A, Ar MC, Ayy?ld?z O, Altunta? F, Okay M, ?ift?iler R, Meletli ?, Soyer N, Mastanzade M, G?ven Z, Soysal T, Karaku? A, Yi?eno?lu TN, U?ar B, G?k?en E, Tu?lular T. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study. Turk J Haematol. 2020 Aug 28;37(3):177-185.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Feb;90(2):162-73.
B?y?ka??k Y, Ali R, Turgut M, Saydam G, Yavuz AS, ?nal A, Ar MC, Ayy?ld?z O, Altunta? F, Okay M, ?ift?iler R, Meletli ?, Soyer N, Mastanzade M, G?ven Z, Soysal T, Karaku? A, Yi?eno?lu TN, U?ar B, G?k?en E, Tu?lular T. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study. Turk J Haematol. 2020 Aug 28;37(3):177-185.
Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol. 2005 Oct;42(4):206-20.
Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 1997 Jun 15;89(12):4628-35.
Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Mic? C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T., Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Chronic Myeloproliferative Diseases Working Party. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008 Jan 15;111(2):666-71.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T., European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 08;350(2):114-24.
CHIEVITZ E, THIEDE T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962 Nov;172:513-23.
Khanal N, Giri S, Upadhyay S, Shostrom VK, Pathak R, Bhatt VR. Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. Leuk Lymphoma. 2016;57(1):129-33
Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002 Sep;71(1):1-6.
Stein BL, Williams DM, Wang NY, et al. Sex differ ences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090-1097.
Passamonti F, Vanelli L, Malabarba L, et al. Clini cal utility of the absolute number of circulating CD34-positive cells in patients with chronic my eloproliferative disorders. Haematologica. 2003; 88(10):1123-1129.
MoliternoAR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloprolifera tive disorders: reciprocity between quantitative JAK2 V617F andMplexpression. Blood. 2006; 108(12):3913-3915.
TefferiA, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21(9): 2074-2075.
Silver RT, Vandris K, WangYL, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially af fected by therapy. Leuk Res. 2011;35(2):177-182.
Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulo cyte activation, and constitutive mobilization of CD34 cellsinto peripheral blood in myeloprolif erative disorders. Blood. 2006;107(9):3676-3682.
VannucchiAM,Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V F mu tation in patients with polycythemia vera or es sential thrombocythemia. Blood. 2007;110(3): 840-846.
MoliternoAR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008;36(11): 1480-1486.
TefferiA, Vardiman JW. Classification and diagno sis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of care diagnostic algorithms. Leukemia. 2008; 22(1):14-22.
JonesAV, Cross NC, White HE, GreenAR, Scott LM. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica. 2008;93(10):1560-1564.
Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011;2(6):485-490.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, OraziA. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera ex erts an impact on clinical outcome. Blood. 2012; 119(10):2239-2241.
Passamonti F, Rumi E, Pietra D, et al.Aprospec tive study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease trans formation and vascular complications. Leukemia. 2010;24(9):1574-1579.
HuangLJ, ShenYM,Bulut GB.Advances in un derstanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol. 2010;148(6):844-852.
Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mu tations: truncated EPO receptors are most fre quently associated with primary familial and con genital polycythemias. Blood. 1997;90(5):2057 2061.
Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica. 2005;90(1):109-116.
AngSO, ChenH,GordeukVR,etal. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28(1):57-62
Percy MJ, Rumi E. Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. Am J Hematol. 2009;84(1): 46-54.
Perrotta S, Nobili B, Ferraro M, et al. Von Hippel Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel clus ter. Blood. 2006;107(2):514-519.
Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2mutants identified in germline DNAof pa tients with polycythemia. Haematologica. 2012; 97(1):9-14.
Pastore YD, Jelinek J,Ang S, et al. Mutations in the VHLgene in sporadic apparently congenital polycythemia. Blood. 2003;101(4):1591-1595.
RumiE, Passamonti F, Della Porta MG, et al. Fa milial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25(35):5630-5635.
Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755 761.
Akada H, Akada S, Gajra A, et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012. Apr 19;119 (16):3779?3789.?
Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010. Aug;150(4):446?455.?
Finazzi G, Vannucchi AM, Martinelli V, et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013. Jun;161(5):688?694.
Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013. Aug;162 (4):498?508.
Lu M, Wang X, Li Y, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012. Oct 11;120(15):3098?3105.
Lu M, Xia L, Li Y, et al. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014. Jul 31;124(5):771?779]
Mascarenhas J, Lu M, Kosiorek H, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019. Aug 8;134(6):525?533
Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013. Apr;123(4):1531?1541.
Casu C, Oikonomidou PR, Chen H, et al. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood. 2016. Jul 14;128(2):265?276.
Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2013. Sep;13(Suppl 2):S307?9
Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004. Feb;32 (2):179?187.
Bogani C, Bartalucci N, Martinelli S, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One. 2013;8(1):e54826.
Delhommeau F, Pisani DF, James C, et al. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci. 2006. Dec;63 (24):2939?2953.
de Melo Campos P, Machado-Neto JA, Eide CA, et al. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget. 2016. Feb 9;7(6):6948?6959.
Fenerich BA, Fernandes JC, Rodrigues Alves APN, et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2 (V617F)-positive myeloproliferative neoplasm cells. Signal Transduct Target Ther. 2020;5(1):5